Evaxion concludes Annual General Meeting
Evaxion (NASDAQ: EVAX) held its Annual General Meeting on April 16, 2026 at its Copenhagen offices.
Rhea-AI Summary
Evaxion (NASDAQ: EVAX) held its Annual General Meeting on April 16, 2026 at its Copenhagen offices. The 2025 Annual Report was approved and the Board proposals passed. Four directors were re-elected and one new director, Jens Bitsch Nørhave, was elected. Minutes are available on the company website.
Positive
- None.
Negative
- None.
Key Figures
- Annual Report year
- 2025
- 2025 Annual Report approved at the Annual General Meeting
Historical Context
-
Phase 2 EVX‑01 one-year extension completed with strong response durability.
-
AI-based polio and CMV vaccine data showcased at World Vaccine Congress.
-
Announcement of upcoming Annual General Meeting and availability of materials.
-
Acceptance of EVX‑01 and AI-Immunology™ data for AACR presentations.
-
Full-year 2025 results, EVX‑01 data, new candidates and extended cash runway.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual General Meeting today at the company’s offices.
The 2025 Annual Report was approved and the Board of Directors’ proposals passed.
Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner and Roberto Prego Pineda were re-elected to the Board of Directors. Jens Bitsch Nørhave was elected to the Board of Directors.
Minutes from the meeting can be found on our website.
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About
Evaxion Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.
With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.
We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, 2 including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.